Index

Note: Page numbers in *italics* refer to figures and tables.

access-based advocacy 266
acid-mediated invasion model 103, 104
acute lymphoblastic leukaemia (ALL) pharmacogenomic testing 261, 265
racial disparities in outcome 269
advocacy, access-/evidence-based 266
agent-based modelling 86
aircraft, decoupling mechanisms 32
Alzheimer’s disease risk 267
angiogenesis 73
molecular species 73–6
promotion 99
tumour-induced 74–6
VEGF-induced 99–100
angiogenesis models 60, 73–8
continuum 76, 77
discrete 76, 77
hybrid 76–7
mechanochemical 76
methodologies 76–8
response models 78
treatment response 81–2
vessel structure stabilizations 77–8
angiopoietins 74
anthracyclines 133
apolipoprotein E4 allele 267
apoptosis evasion 11
artificial intelligence techniques 68
atoms, three-dimensional arrangement 127
AUTODOCK 137, 138
automatic flight control system (AFCS) 32
Available Chemical Dictionary (ACD) 138
Bayesian networks 86
BCR-ABL ATP-binding pocket 53
bevacizumab 53
BiDil 269
binding energy prediction 137
BioBank (UK) 239–40
Biocarta 84
bioinformatics 96
data leakage risks 253–4
informed consent 239–40
NCI infrastructure development 158–62,
163, 164
research team confidentiality responsibility 245
social concerns 267–8
structural 127–38
*see also* crystallography, macromolecular;
molecular modelling
biological complexity 7–8
constitutive 9–11
dynamic 9, 11–12
evolved 9, 12–14
*see also* systems biology
Biomedical Informatics Research Network (BIRN) 164, 165–6
biomedical software, high-risk cancer cell clusters 216–17
SoDIS analysis 224–5, 226, 227–8, 229–30
biosimulation 110
biotechnology companies, rare disease research 263–4
BLASTN program 180
blood flow 74–5
mechanical stimulus 98
blood vessels, shear forces/stresses 74–5, 98
Boolean network 78, 85
probabilistic 86
Boolean–Bayesian hybrid model 86
breast cancer
molecular marker guidelines 260–1
racial disparities in outcome 268
technology failure 266
see also trastuzumab
British Medical Association, professional guidance 249
Byzantine Generals Problem 33–4

caARRAY database 163
CaBIG (Cancer Biomedical Information Grid) 49
c-abl 128, 129
caCORE 6, 21
infrastructure 162
calMAGE database 159
Caldicott Guardians 206–7, 248
caMOD (Cancer Model Organisms Database) 160, 161
application 162
cancer
dormancy 37
mortality 185
signals 171–2
susceptibility modelling 167
see also treatment resistance
cancer cells
acidification of environment 103
clonogenic density 114
cluster identification program 216–17
geometrical of discretizing mesh 112, 114
high-risk cluster identification 216–17
SoDIS analysis 224–5, 226, 227–8, 229–30
hypoxia-induced quiescence 100
phenotypes 8
robustness 7, 11, 30
subclusters 34
Cancer Genome Anatomy Project (CGAP) 172
Cancer Molecular Analysis project 46
cancer registry information 201
cancer research communities, meeting needs 188–9, 190
cancer robustness theory 29–40
cancer system 34–6
computational tools 39–40
evolvability 32–4
mechanisms 31–2
therapy strategies 36–8
trade-offs 32–4
treatment efficacy index 38–9
cancer systems
complexity 97
constitutive 9–11
dynamic 9, 11–12
evolved 9, 12–14
taxonomy 9–14
feedback loop control 38
instability 111
modelling 14–16, 17–19, 20
robust 34–6
simulation 14–16, 17–19, 20
CancerGRID 6, 22
carcinogenesis 101
carcinoma nodules 65
Cartesian coordinate frame 127
C-Change – Collaborating to Conquer Cancer 188
cdk4 drug design 135
cDNA sequences 172–3, 175
full-length 178, 180
cDNA xProfiler 175–6
cell cycle
hypoxia-induced arrest 100
phases 112
cell–cell interactions 98
CellML 24
cellular automata 68–9, 72–3
formalisms 70–1, 72–3
hybrid approach 71, 97, 103–4
lattice–gas two-dimensional approach 71
models 98, 99
stochastic model 70–1
three-dimensional models 97
treatment response models 82
two-dimensional models 97
cellular evolution 12–14
Center for Systems Biology (US) 166
Central Office of Research Ethics Committees (UK) 205
chemical reaction–diffusion dynamics 71
chemotaxis 71
angiogenesis modelling 77
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>chemotherapy</td>
<td>119</td>
</tr>
<tr>
<td>response simulation</td>
<td>118–19</td>
</tr>
<tr>
<td>chromosome 1q25, expressed sequences</td>
<td>182</td>
</tr>
<tr>
<td>chromosome 21</td>
<td></td>
</tr>
<tr>
<td>gene identification</td>
<td>181</td>
</tr>
<tr>
<td>novel transcripts</td>
<td>181–2</td>
</tr>
<tr>
<td>chromosome 22, gene identification</td>
<td>181</td>
</tr>
<tr>
<td>chromosome instability</td>
<td>34, 37</td>
</tr>
<tr>
<td>chromosome mutations</td>
<td>13</td>
</tr>
<tr>
<td>chronic myeloid leukaemia (CML) treatment response modelling</td>
<td>80, 81</td>
</tr>
<tr>
<td>see also imatinib</td>
<td></td>
</tr>
<tr>
<td>c-kit receptor tyrosine kinase</td>
<td>128</td>
</tr>
<tr>
<td>CLEF (Clinical E-Science Framework)</td>
<td>22</td>
</tr>
<tr>
<td>project approach</td>
<td>251–2</td>
</tr>
<tr>
<td>client needs</td>
<td>218</td>
</tr>
<tr>
<td>clinical care, health data</td>
<td>235–6</td>
</tr>
<tr>
<td>clinical decision-making, error avoidance</td>
<td>53</td>
</tr>
<tr>
<td>clinical information systems</td>
<td>201</td>
</tr>
<tr>
<td>Clinical Laboratory Improvement Amendments (1988, US)</td>
<td>258, 259</td>
</tr>
<tr>
<td>clinical research database, accountability</td>
<td>239</td>
</tr>
<tr>
<td>clinical trials</td>
<td></td>
</tr>
<tr>
<td>ethical issues</td>
<td>233–55</td>
</tr>
<tr>
<td>EU Directive</td>
<td>243</td>
</tr>
<tr>
<td>information systems</td>
<td>201</td>
</tr>
<tr>
<td>clinical utility</td>
<td>261</td>
</tr>
<tr>
<td>colorectal cancer</td>
<td></td>
</tr>
<tr>
<td>chemotherapy clinical trial</td>
<td>187</td>
</tr>
<tr>
<td>tissue use</td>
<td>205–6</td>
</tr>
<tr>
<td>common mode failure</td>
<td>36</td>
</tr>
<tr>
<td>complex systems</td>
<td></td>
</tr>
<tr>
<td>simulations</td>
<td>86–7</td>
</tr>
<tr>
<td>see also biological complexity; systems biology</td>
<td></td>
</tr>
<tr>
<td>complex trait analysis</td>
<td>167</td>
</tr>
<tr>
<td>computational systems biology</td>
<td>5</td>
</tr>
<tr>
<td>computer simulation, treatment response</td>
<td>109–21</td>
</tr>
<tr>
<td>conceptual models</td>
<td>7–8</td>
</tr>
<tr>
<td>confidentiality</td>
<td></td>
</tr>
<tr>
<td>bioinformatics research team responsibility</td>
<td>245</td>
</tr>
<tr>
<td>NHS Code of Practice</td>
<td>248</td>
</tr>
<tr>
<td>patient information</td>
<td>206–7</td>
</tr>
<tr>
<td>policies</td>
<td>252, 253</td>
</tr>
<tr>
<td>professional guidance</td>
<td>249</td>
</tr>
<tr>
<td>UK Common Law</td>
<td>244</td>
</tr>
<tr>
<td>consent/informed consent</td>
<td></td>
</tr>
<tr>
<td>access to health records</td>
<td>237</td>
</tr>
<tr>
<td>bioinformatics</td>
<td>239–40</td>
</tr>
<tr>
<td>boundaries</td>
<td>240</td>
</tr>
<tr>
<td>DNA analysis</td>
<td>247</td>
</tr>
<tr>
<td>documented</td>
<td>236</td>
</tr>
<tr>
<td>durability</td>
<td>240</td>
</tr>
<tr>
<td>explicit/express</td>
<td>239</td>
</tr>
<tr>
<td>obligations</td>
<td>248</td>
</tr>
<tr>
<td>obtaining from patients</td>
<td>207, 250</td>
</tr>
<tr>
<td>patient-identifiable data</td>
<td>234–5</td>
</tr>
<tr>
<td>personal information use</td>
<td>239–40</td>
</tr>
<tr>
<td>pre-existing</td>
<td>250</td>
</tr>
<tr>
<td>specimens for medical research</td>
<td>247</td>
</tr>
<tr>
<td>constructive models</td>
<td>62</td>
</tr>
<tr>
<td>control theory</td>
<td>111</td>
</tr>
<tr>
<td>Conway’s Game of Life</td>
<td>72</td>
</tr>
<tr>
<td>cost-effectiveness analysis</td>
<td>261, 262</td>
</tr>
<tr>
<td>Council of Europe Recommendation on health data</td>
<td>242–3</td>
</tr>
<tr>
<td>cryoaablation of prostate</td>
<td>119</td>
</tr>
<tr>
<td>crystal structures</td>
<td>131, 132</td>
</tr>
<tr>
<td>crystallography, macromolecular</td>
<td>129–35</td>
</tr>
<tr>
<td>high-throughput methods</td>
<td>134</td>
</tr>
<tr>
<td>structure storage</td>
<td>131–2</td>
</tr>
<tr>
<td>Darwinian environment</td>
<td>100, 101, 102–3</td>
</tr>
<tr>
<td>data</td>
<td></td>
</tr>
<tr>
<td>anonymized</td>
<td>207, 250–2</td>
</tr>
<tr>
<td>computational management</td>
<td>5</td>
</tr>
<tr>
<td>depersonalization</td>
<td>242</td>
</tr>
<tr>
<td>electronic for patients in clinical trials</td>
<td>233–55</td>
</tr>
<tr>
<td>electronically-held</td>
<td>236–7</td>
</tr>
<tr>
<td>genetic</td>
<td>243</td>
</tr>
<tr>
<td>integration</td>
<td>20–2, 46–7</td>
</tr>
<tr>
<td>leakage of research</td>
<td>253</td>
</tr>
<tr>
<td>machine analysis</td>
<td>53</td>
</tr>
<tr>
<td>resource availability</td>
<td>50</td>
</tr>
<tr>
<td>sharing</td>
<td>46–7, 50, 52</td>
</tr>
<tr>
<td>drug design</td>
<td>52–3</td>
</tr>
<tr>
<td>standards</td>
<td>20–4</td>
</tr>
<tr>
<td>see also health data; patient-identifiable health data</td>
<td></td>
</tr>
<tr>
<td>data mining</td>
<td>83–4</td>
</tr>
<tr>
<td>computational</td>
<td>5</td>
</tr>
<tr>
<td>sequence databases</td>
<td>172</td>
</tr>
<tr>
<td>vertical genomics</td>
<td>16, 17–19, 20</td>
</tr>
<tr>
<td>data protection, EC directive</td>
<td>242</td>
</tr>
<tr>
<td>Data Protection Act (1998, UK)</td>
<td>204, 206, 244–5</td>
</tr>
<tr>
<td>anonymized data</td>
<td>250–1</td>
</tr>
<tr>
<td>databases</td>
<td></td>
</tr>
<tr>
<td>information storage</td>
<td>178</td>
</tr>
<tr>
<td>sequence mining</td>
<td>172</td>
</tr>
<tr>
<td>see also named databases</td>
<td></td>
</tr>
</tbody>
</table>
INDEX

data-driven research 6, 15
decision support systems, computer-based 53
decoupling 32
decoy use 38
de-identification 235
techniques 251–2
Department of Health (UK) policies 247–8
devices, regulation 259
diabetes mellitus 34
diagrammatic cell language (DCL) 86
differential equations 63, 69, 79
  see also ordinary differential equations;
  partial differential equations
diffusion-reaction models 98
Digital Gene Expression Displayer (DGED) 175–6
DIP 84
disclosure
  inappropriate 252, 253–4
  professional guidance 248–9
discrete state cell-cycle-based radiotherapy
  response model 120
discretizing mesh 112, 114, 119
disease
  minority populations 268–9
  orphan 263–4
  system failure 34
disparities, health 268–70
DNA analysis, consent 247
DNA damage, p53 oscillatory expression 32
DNA microarrays 120
DOCK 137, 138
docking program, automated 136, 137–8
dormancy, cancer 37
drug(s)
  candidate screening 131
  genotype-specific marketing 269
  molecular targeted 128
  orphan 263–4
drug delivery
  fractal models 86
  protocols 100
drug design
  data sharing 52–3
  in silico screening 137–8
  structure-based 135–7
drug development 185–209
  clinical 186
  Phase 1 190
  social subsidies 264
drug discovery, rational 135–7
  structure determination 131
dynamic pathway models 60, 83–6
E-cell 87
e-GIF 199
Electronic Health Record (EHR) 236–7
  accountability 239
  anonymized repository 251
  ethical principles 238
  legal principles 238
eMICE website 158, 159, 164
employers, pharmacogenomic test
  information 267
endothelial progenitor cells (EPCs) 81–2
environment
  Darwinian 100, 101, 102–3
  perturbations 32–3
enzyme structures 132, 133
epidemiological statistical techniques 61
epidermal growth factor (EGF)
  pathway 12
  signal transduction pathway model 85
ethical framework, National Cancer Tissue
  Resource 202–4, 207
ethics
  clinical trials 233–55
  Electronic Health Record 238
  health record information 237–9
  pharmacogenomics 264–70
  software design 213–30
  tissue sample handling 238–9
  ethnic health disparities 268–70
European Bioinformatics Institute (EBI) 49
European legislation
  health data 242–3
  orphan drugs 264
  pharmacogenomics 259
European Union Clinical Trials Directive 243
evidence-based advocacy 266
evolution
  cellular 12–14
  somatic 101, 102–3
  evolvability 32–3
  robustness 30
  exon/intron boundaries 180
expressed sequence tags (ESTs)
  172, 173
  clusters 182
International Database of Cancer Gene Expression 176–7
mapping 182
extracellular matrix composition 74

FAPESP/LICR Human Cancer Genome Project 172–82
methodology 173
organization 172–3
sequence analysis 173–4
tumour transcriptome 175–8, 179, 180–2
finite difference time domain (FDTD) technique 114
First Genetics Trust 202
Food and Drug Administration (US)
orphan drugs 264
pharmacogenomics regulation 258–60
formalisms 61–2
cellular automata 70–1, 72–3
generalized 62–4
treatment response models 78
fractal models 86
fragility 33
robustness trade-off 37

Freedom of Information Act (2000, UK) 246
gastrointestinal stromal tumours 128, 187
gene(s)
cancer-related set 176
catalogues 175
identification 180
prediction programs 180
stability 7–8
gene expression
modes 171
pathway dynamics link 11–12
survey 177
Gene Library Summarizer (GLS) 175–6
General Medical Council (UK), professional guidance 248–9
genetic abnormalities 7
genetic buffering 32
genetic data, Council of Europe Recommendation 243
genetic heterogeneity, intratumoural 34, 36–7
enhancement by somatic recombination 37
molecular-targeted drugs 37–8

genetic information, patient 238
genome
analysis 180
deregulation 8
unstable 13
see also human genome
genomic technologies, health insurers 261–2
genomics 3, 4
integration/interrogation of research results 202
structural 134
vertical 16, 17–19, 20
genotypic TPMT testing 261, 265, 269–70
Gert’s morality theory 225
Gleevec® see imatinib
glioblastoma multiforme 116, 117–18
temozolomide treatment 119
Glivec® see imatinib
glucose metabolism
altered 102
anaerobic 103
glycolysis
aerobic 102
constitutive upregulation 103
inhibition 102
glycomics 3, 4
Gompertz function 63–4, 66–7
good practice, patient information 248
growth models 60, 62–71
avascular 65–6
formalisms 66–9
non-traditional 69–71
growth retardation, avascular 66
haptotaxis, angiogenesis modelling 77
health
disparities 268–70
WHO definition 214
Health and Social Care Act (2001, UK) 207, 246–7
health data
access rights 237, 245
anonymized 207, 250–2
clinical care 235–6
consented research 235–6
European legislation 242–3
genetic 243
ISO standard 241–2
key-coding 250
health data (Continued)
patient-identifiable 233–40, 240–50
flow principles 247–8
legislation 240–7
policies 247–50
protection 250, 252–5
pseudonymized 250–2
researchers’ access to 249
secondary use 249–50
sharing 246–7
UK legislation 244–7
health information
disclosures 248–9
genetic of patient 238
given to patients 236–7
global integration 238
NHS governance 248
right of access 246
third-party access to pharmacogenomic tests 266–7
uses 235
Health Insurance Portability and Accountability Act (US) 268
health insurers
 genomic technologies 261–2
health disparities 268
pharmacogenomic test information 267
Health Protection Agency (UK) 207
health records
access for research 237
durable 237
ethical requirements for information 237–9
information 236–7
retrospective use 250
rights to access 237
healthcare systems, integrated informatics platform engagement 50–1
healthcare technology evaluation 261–3
HER2 gene 187
expression 261
Herceptin® see trastuzumab
heuristic models 61
high optimized tolerance (HOT) systems 33
high-throughput methods 3–4, 83–4
crystallography 134
eukaryotic protein expression 134
macromolecular crystallography 131
HIV/AIDS, decoy virus use 38
homology modelling 135
HORUS model 248
host–tumour dynamics 7
feedback control 38
Hsp90, genetic buffering 32
Human Brain Project 164
Human Cancer Genome Project, see FAPESP/LICR Human Cancer Genome Project
human genome
economic gain from project 52
genes 180
proteins 134
human rights, health disparities 268
Human Rights Act (1998, UK) 245–6
Human Tissue Authority (UK) 206
Human Tissue Bill (2004, UK) 202–3, 204–7, 247
patient-identifiable health data 234
hybrid models 60–1
hypothesis generation/validation 186, 190
hypothesis-driven research 6, 15
hypoxia 100
hypoxia-induced factor-1 (HIF-1) 99
overexpression 35
up-regulation 38
ideological models 62
imatinib 36, 53, 128–9, 187
immunity–tumour interaction 70
immunohistochemistry, diagnostic procedures 148
immunotherapeutic strategies 80
impossibility 225, 227
in silico experimentation 59, 60
in silico libraries 136, 137–8
in silico oncology 110
in silico screening for drug design 137–8
informatics
 crystallographic 131–4
ethics in clinical trials 233–55
Mouse Models of Human Cancers
 Consortium programme 156–8
NCRI strategy 191
in silico screening 137–8
social concerns 267–8
structural 131–4
tools 175–6
see also bioinformatics
informatics platform, integrated 45–54
benefits 51–3
building 46–7
data sharing 50, 52–3
development 49–51
drug design 52–3
education 50
healthcare system engagement 50–1
integration 49
resource availability 50
reward systems 49–50
training 50
information see health information; patient information; personal information
information systems, National Cancer Tissue Resource 194–5
architecture 195–6, 197–8, 199–204
information technology (IT) NHS 196, 199
UK National Programme 199
informed consent see consent/informed consent
Integrated Database of Human Cancer (IDHC) 178, 179
data sets 180
gene discovery use 180–2
integration programmes 49
International Conference on Harmonization 264
International Database of Cancer Gene Expression 175, 176–7
International Medical Informatics Association 225
International Organization for Standardization (ISO) 241–2
In-Vitro Diagnostic Devices Directive (EU) 259
ISOG avascular tumour growth simulation model 112–14
discretizing mesh 119
Joint Clinical Information System (Cambridge, UK) 199
justice, health disparities 268
KEGG 84
key-coding 250
kinases, homology modelling 135
knowledge discovery 5–6
mathematical modelling 15
wet–dry cycles 6
lead compounds, perturbation selection 40
legislation
Electronic Health Record 238
European 242–3, 259, 264
patient-identifiable health data 240–7
pharmacogenomics 258–60
tissue sample handling 238–9
tissue use 202–7
UK 244–7
US mechanisms 260
legitimate infringement 225, 227
leukaemia see acute lymphoblastic leukaemia (ALL); chronic myeloid leukaemia (CML)
Library Finder 175–6
linear quadratic (LQ) model 79, 83
linkage mechanisms, longitudinal 247
LISA system 53
literature, manual curation 145, 146
locality-interaction modelling 69
logistic growth function 64
macromolecule structures 131–2
macrophages, chemotaxis in tumour cluster 35
malignant phenotype acquisition 100
properties 101–2
MAP kinase pathway 12
overexpression 85
mathematical modelling 59–88, 95–6
complex biological system simulation 86–7
computational 5
diffusion-reaction 98
efficacy–toxicity 119
multiscale 96–8
types of models 60–1
see also angiogenesis models; cellular automata; dynamic pathway models; growth models; population models; treatment response models; tumour(s), vascular modelling
MATLAB 85
MDR1 gene 35
medical informatics, social concerns 267–8
Medical Research Council (UK) professional guidance 249
6-mercaptopurine 265
metabolic activity, spatial distribution 113
metabolic networks 10
metabolomics 3, 4
metastases, tumour vascularization 73
Michaelis–Menten equations 84–5
INDEX

microarrays 83–4, 120
high-throughput DNA 84
model organisms 166
models/modelling
agent-based 86
cancer
  models database 162, 163
  resistance 119, 167
  susceptibility 167
  systems 14–16, 17–19, 20
cancer biology model connections 164
conceptual 7–8
constructive 62
heuristic 61
homology 135
ideological 62
integrating with human cancer research 155–67
molecular 135–8
multicellular tumour spheroids (MTS) 64–6, 68, 71
normative 61
NTCP of radiotherapy-induced normal tissue complications 120
pedagogical 61
proliferative cell behaviour 86
response behaviour 78–83
spatiotemporal of cell 84
systems vertical genomics 16, 17–19, 20
terminology 60
tumour vascular 98–100
vascular 98–100
see also mathematical modelling;
  Monte-Carlo models; mouse models
modularity, perturbation isolation 31
molecular marker guidelines 260–1
molecular modelling 135–8
molecular networks, integration into tumour behaviour simulations 120
molecular signatures 186
molecular-targeted drugs 37–8
molecules, three-dimensional architecture of surface 127–8
Monte-Carlo models
  method 83
  radiotherapy response simulation 114, 115, 116, 117–18
morality theory of Gert 225
mouse models
database 157
development 144
genetic 164
histopathology image collections 159, 160
manual curation of data 160
terminology consistency 159
Mouse Models of Human Cancers Consortium (MMHCC) 156
databases 160–1
domains 165
informatics 156–8
tumour histopathology images 161
Mouse Phenome Project 164
Mouse Tumour Biology (MTB) database 143–52
  connecting with related databases 150
  content 145
  data acquisition 145–8
  histopathology images 147–8
  Tumour Frequency Grid 148, 151
  using 147, 148, 149–50, 151
mRNA sequences 173, 174
multicellular tumour spheroids (MTS) models 64–6, 68, 71
Multi-centre Research Ethics Committee (MREC) 206, 207
multi-drug resistance 35
multiset rewrites 76
mutagenesis, discrete time stochastic model 86
mutations 7–8
  bystander 8
  cancer genes 13
  chromosomal 13
  modelling 86
  oncogene 7–8
  randomness 13
National Cancer Institute (US) 155–6
bioinformatics infrastructure
  core 162
  development 158–62, 163, 164
Cancer Genome Anatomy Project 175–6
Center for Bioinformatics (NCICB) 49, 156, 158–62, 163, 164
Integrative Cancer Biology Program 166
medical imaging infrastructure 161
Molecular Analysis of Cancer 162–3
Mouse Models of Human Cancers Consortium programme 156–64
small animal imaging 161
| National Cancer Research Institute (UK) | 187–8  |
| Consumer Liaison Group       | 207    |
| informatics platform       | 47–9   |
| Informatics Strategy      | 191    |
| National Cancer Tissue Resource | 191–208 |
| planning matrix         | 48–9   |
| Strategic Framework for the Development of Cancer Research Informatics | 6, 21–2 |
| strategic partnerships   | 49     |
| National Cancer Tissue Resource (UK) | 191–208 |
| access to academic researchers/industry | 202 |
| clinical outcome information | 192 |
| components                 | 193, 196, 197–8, 199–202 |
| consent                     | 204–7  |
| donor information            | 200–1  |
| ethical approval             | 207    |
| ethical framework            | 202–4  |
| information system          | 194–5  |
| architecture                 | 195–6, 197–8, 199–204 |
| functionality                | 194–5  |
| integration/interrogation of results | 202 |
| legal framework              | 202–4  |
| local acquisition centres   | 196, 197, 199 |
| local centre systems        | 201    |
| new systems                 | 200–1  |
| patient identity protection | 203–4  |
| patient information confidentiality | 206–7 |
| sample information           | 200, 201 |
| security                    | 203–4, 207 |
| tissue supply                | 192    |
| tracking systems            | 199–200 |
| unintended identification   | 207    |
| workflow processes          | 198    |
| National Cancer Waiting Times Project (UK) | 199–200 |
| National Comprehensive Cancer Network (US) | 260–1  |
| National Data Spine (UK)    | 204    |
| National Health Information Infrastructure (US) | 267–8  |
| National Health Service (UK) | Confidentiality Code of Practice | 248  |
| information governance      | 248    |
| integrated informatics platform engagement | 50–1 |
| IT systems                  | 196, 199 |
| molecular revolution benefits | 185  |
| paraffin-embedded tissue archive | 192  |
| National Institute for Clinical Excellence (UK) | 262–3 |
| National Partnership for Advanced Computational Infrastructure (US) | 164–5 |
| National Translational Cancer Research Network (NTRAC) | 188–9, 191 |
| neovascularization of capillaries | 73   |
| network biology             | 10–11  |
| neurobiology information    | 164    |
| NF-κB                       |         |
| signal transduction pathway | 85     |
| treatment response model    | 80     |
| normative models            | 61     |
| NTCP model of radiotherapy-induced normal tissue complications | 120 |
| nuclear magnetic resonance (NMR) spectroscopy |         |
| macromolecular structure determination | 129 |
| macromolecular structure storage | 131–2 |
| Nuffield Council in Bioethics | 263, 264, 266 |
| Nuffield Trust, professional guidance | 249–50 |
| omic technologies           | 3, 4, 5 |
| oncogene/pathway addiction | 7      |
| oncogenes                   |         |
| defect correction           | 7      |
| mutations                   | 7–8    |
| ONSA (Organization for Nucleotide Sequencing and Analysis) | 172 |
| ontologies, translational cancer research | 22–3 |
| open reading frame ESTs see ORESTES ordinary differential equations (ODE) | 67, 68, 69 |
| dynamic pathway models      | 85, 86 |
| treatment response models   | 80–1, 82 |
| ORESTES sequences           | 173–4, 176 |
| chromosome                  | 22, 181 |
| integration with genome sequence | 180 |
| methodology                 | 173    |
| orphan diseases/drugs       | 263–4  |
| OWL ontology exchange language | 23   |
| oxygen                      |         |
| concentration heterogeneity effects | 98–9 |
| enhancement ratio (OER)     | 79     |
| p27                         | 100    |
| p53 oscillatory expression on DNA damage | 32   |
partial differential equations (PDE) 67, 69, 71
treatment response models 82
Pasteur effect 102
pathobiology of cancer 7
pathology information systems 201
paths
conceptualization 84
data 84
dynamics and gene expression link 11–12
see also dynamic pathway models
patient(s)
care and risk assessment 217
choice in pharmacogenomics 266
consent 234–5
documented 236
informed 207
de-identification 235
electronic data ethics in clinical trials 233–55
genetic information 238, 243
health record information 237–9
identity
protection 203–4, 206–7
unintended identification 207
information given 236–7
personal information classes 235–7
rights 218
patient administration systems 201
patient information
confidentiality 206–7
disclosures 248–9
good practice 248
personal
classes 235–7
obtaining consent for use 239–40
professional guidance 248–50
Patient Information Advisory Group (PIAG) 207
personal health data sharing 246
patient-identifiable health data 233–40
flow principles 247–8
legislation 240–7
policies 247–50
professional guidance 248–50
pedagogical models 61
personal information
classes 235–7
obtaining consent for use 239–40
see also health data; health information;
patient information
perturbations
computational analysis 40
environmental 32–3
robustness against 33
Peterborough Tissue Bank 202
P-glycoprotein (P-gp) 35
pharmaceutical companies, economic incentives
for rare disease research 263–4
pharmacogenomics 14, 257–70
access 268
benefits 261–3
clinical utility 261
costs 261–3
drugs 258–61
economics 263
effects 264–70
evaluation criteria 260–1
family member issues 266–7
genotype-specific marketing of drugs 269
health disparities 268–70
legislation 258–60
off-label use 259
patient choice 266
physician competence 265–6
psychosocial issues 266
regulations 258–60
sponsors 259–60
technology failure 266
tests 258–61
third-party access to information 266–7
therapies tailored to minority groups 269
unapproved use 259
White privilege perpetuation 269
PharmGKB pharmacogenomics database 46
phenotype
cancer 8
malignant 100, 101–2
physicians, competence in
pharmacogenomics 265–6
Physiome Project 105
platelet-derived growth factor (PDGF) 74–5
policies
confidentiality 252, 253
patient-identifiable health data 247–50
population models 100–3
positron emission tomography,
fluoro-deoxyglucose (Fdg pet) 102
PROCHECK algorithm 132
professional guidance, patient
information 248–50
INDEX

proliferative cell behaviour modelling 86
prostate cryoablation 119
Protégé-2000 23
protein(s)
  folding pattern predictions 135
  microarrays 120
  structures 132, 133
  prediction 135
Protein Data Bank (PDB) 131–3
human genome proteins 134
Protein Database 129
protein kinase superfamily 133
protein–drug structures 133
protein–ligand complexes 132
protein–protein interaction data 84
proteomics 3, 4
  integration/interrogation of research results 202
pseudodormancy 37
public health, health disparities 268
quality-adjusted life years (QALYs) 262–3
QUASAR clinical trial, tissue use 205–6
rational health disparities 268–70
radiation, ionizing, signalling pathway overexpression 85
radiochemotherapy, electric pulse local application 119
radiotherapy
  discrete state cell-cycle-based response model 120
  NTCP model of normal tissue complications 120
  optimization 83
  response simulation 114, 115, 116, 117–18
random walks 76, 77
reaction diffusion system 98
regulations for pharmacogenomics 258–60
research, secondary 249–50
Research Ethics Committees 205
  patient-identifiable health data 234
research repository
  anonymized 251
  longitudinal 250
researcher submissions to databases 145, 146
resource allocation 263
Resource Description Framework (RDF) 22
response behaviour modelling 78–83
risk analysis
  ethical 217–18
  software design 215–16
  statistical 217
risk identification in software design 214–16
robustness
  alternative (fail-safe) mechanisms 31
  analysis 39–40
  biological systems 30
  control 38–9
  decoupling mechanism 32
  fragility trade-off 37
  intrinsic features of systems 32–4
  mechanisms 31–2
  modularity 31
  against perturbations 33
  system control 31
  theory of 29–40
SBW (Systems Biology Workbench) 20
scale-free networks 33
scar tissue formation 104–5
SCIpath (Systems Complexity Interface for pathways) project 16, 18–19, 20
self-organized criticality (SOC) 33
semantic web technologies 22–4
serial analysis of gene expression (SAGE) data 177–8
  Genie web portal 178
  tags 172, 176, 177, 178
  service concept 218
signalling
  networks 10–11, 84–5
  pathways
    overexpression 85
    redundancy 134
    transduction inhibition 12
    vertically integrated analysis 16, 18–19, 20
  simulation, terminology 60
Singapore Tissue Network 188
slime mould pattern formation 104
small interfering RNA (siRNA) immunotherapy 80
socio-economic factors, health disparities 268–70
software design
  absence of negative effects on users 218
  ethics 213–30
  failure 214
  fiduciary model 218
software design (Continued)
paternalistic model 217–18
Project Auditor 219–20
project type identification 220
responsibilities of designers 218
risk identification 214–16
surprising impacts 214
Software Development Impact Statement
(SoDIS) 214–16, 218–24
Active Concerns Detail Report 228, 230
analysis screen 220, 222
concerns 228, 229
ethical concern identification 222, 223–4
goals 218–19
mitigation process 223–4
potential ethical issue identification 222
process 219–24
Project Auditor 219–20
risk analysis principles 215–16
solutions 228, 229
stakeholders
identification 220, 221, 225, 226, 227–8
role identification 220
task identification 221
Software Engineering Code of Ethics and
Professional Practice 218
somatic evolution 100, 102–3
somatic recombination 37
Spanish National Tumour Bank 202
spatiotemporal modelling of cell 84
specimens for medical research, consent 247
sponsors, pharmacogenomic 259–60
stability gene mutations 7–8
state transitions 112
statistical analysis of risk 217
statistical techniques, epidemiological 61
STI-571 81
stochasticity, extrinsic 85
synchrotron sources 130, 131
systems
control robustness 31
failures 33–4
simulation of complex 86–7
understanding 8
vertical genomics modelling 16, 17–19, 20
vulnerability 14
systems biology 4–6, 171–2
biomolecular networks 10–11
complex system simulations 86–7
computational 5
treatment
  efficacy index 38–9
  normal tissue response 120
  strategies 36–8
  toxicity response 120
  treatment resistance 8, 11, 29
  models 167
    efficacy–toxicity 119
  multi-drug 35
  treatment response models 60, 78–83
    cellular automata 82
    computer simulation 109–21
    chemotherapy 118–19
    radiotherapy 114, 115, 116, 117–18
    tumour growth 111–14
  formalisms 78
  mechanistic-based 78
  radiotherapy optimization 83
  therapy optimization 78
  tumour(s)
    altered glucose metabolism 102
    behaviour simulations 120
    classification systems 159–60
    control probability 79
    dormancy 37
    expansion 112
    geometry of imageable lesion 113
    growth
      avascular 69–71
      characters 62
      early 103
      simulation 111–14
      nomenclature 145–6
      systems 159–60
    shrinkage 113
    suppressor mutations 7–8
    transcriptomes 175–82
    vascular modelling 98–100
    vascularization 73
    see also growth models
  tumour angiogenic factors (TAFs) 74, 75,
    signalling 77–8
    tumour chords 64–6
    tumour clusters 34, 35
  tumour spheroids
    formation 112
    multicellular 64–6, 68
  tumour-associated macrophages (TAMs) 35
    decoy mechanisms 38
  tumour–host interactions 35
  UK BioBank 239–40
  UK legislation 244–7
  UniGene 178
    vascular endothelial growth factors
      (VEGF) 74, 75
      angiogenesis induction 99–100
      cancer cell secretion 99
    vascular modelling 98–100
    vascularization processes 73
    vasculogenesis 73
    Virtual Cell platform 86, 87
    Virtual Northern 175–6
    virtual sequencing network 172
    von Bertalanffy growth function 64
    Warburg effect 102
    World Health Organization (WHO) health
      definition 214
    wound healing, scar tissue formation
      104–5
    XML syntax 22
      exchange standards for pathways/models 23–4
    X-ray crystallography 129–35
    yeast model system 39–40

Index compiled by Jill Halliday